Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Lytic effector cell function in schizophrenia and depression.

A Urch1, C Müller, H Aschauer

  • 12nd Department of Medicine, University Hospital, Vienna, Austria.

Journal of Neuroimmunology
|July 1, 1988
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

ESMO-Magnitude of Clinical Benefit Scale for haematological malignancies (ESMO-MCBS:H) version 1.0.

Annals of oncology : official journal of the European Society for Medical Oncology·2023
Same author

Dabrafenib plus trametinib in patients with BRAF V600E-mutant anaplastic thyroid cancer: updated analysis from the phase II ROAR basket study.

Annals of oncology : official journal of the European Society for Medical Oncology·2022
Same author

Reply to Third consensus on medical treatment of metastatic breast cancer.

Annals of oncology : official journal of the European Society for Medical Oncology·2020
Same author

Brain metastases as first manifestation of advanced cancer: exploratory analysis of 459 patients at a tertiary care center.

Clinical & experimental metastasis·2018
Same author

Decreased body mass index is associated with impaired survival in lung cancer patients with brain metastases: A retrospective analysis of 624 patients.

European journal of cancer care·2017
Same author

Next-generation sequencing identifies major DNA methylation changes during progression of Ph+ chronic myeloid leukemia.

Leukemia·2016
Same journal

Clinical features, imaging findings, and treatment outcomes of optic neuritis associated with anti-CRMP5 antibodies: a systematic review.

Journal of neuroimmunology·2026
Same journal

Serum IDO1 and β-catenin levels in patients with multiple sclerosis with and without atherosclerosis: A case-control study.

Journal of neuroimmunology·2026
Same journal

Neurological sequelae of Long COVID: Pathophysiological mechanisms, diagnostic advances, and therapeutic perspectives.

Journal of neuroimmunology·2026
Same journal

Corrigendum to 'Role of CD40 in prion disease and the immune response to recombinant PrP' [Journal of Neuroimmunology 257 (2013) 21-27/475655].

Journal of neuroimmunology·2026
Same journal

Clinical characteristics of IgG4-related hypertrophic pachymeningitis with and without serum ANCA positivity.

Journal of neuroimmunology·2026
Same journal

Chronic neuroinflammation after acute SARS-Cov-2 infection induces retinal damage in the hACE2 transgenic mouse model.

Journal of neuroimmunology·2026
See all related articles

Natural killer (NK) cell activity and antibody-dependent cellular cytotoxicity (ADCC) are impaired in patients with schizophrenia and depression. Treatment reversed these deficits in schizophrenia but not depression, suggesting distinct immune profiles.

Area of Science:

  • Immunology
  • Neuroscience
  • Psychiatry

Background:

  • Natural killer (NK) cell activity and antibody-dependent cellular cytotoxicity (ADCC) are crucial immune functions.
  • Previous research suggests potential immune dysregulation in psychiatric disorders.

Purpose of the Study:

  • To investigate NK cell activity and ADCC in patients with schizophrenia and depression.
  • To determine the effects of psychopharmacologic treatment on these immune functions.
  • To explore the role of serum factors in modulating NK activity and ADCC in these patient groups.

Main Methods:

  • Assessed NK cell activity and ADCC in patients with schizophrenia, depression, and healthy controls.
  • Evaluated immune function before and after psychopharmacologic treatment.

Related Experiment Videos

  • Investigated the effect of patient-derived serum on NK activity and ADCC in vitro.

    • Main Results:

    • Significantly lower NK activity and ADCC were observed in both schizophrenia and depression patient groups compared to controls.
    • Treatment with neuroleptics and antidepressants increased NK activity and ADCC in schizophrenic patients, but not in depressed patients.
    • Serum from untreated schizophrenic patients inhibited ADCC and NK activity, an effect diminished or absent in treated patients and absent in depressed patients.

    Conclusions:

    • Lytic effector mechanisms, including NK activity and ADCC, are impaired in schizophrenia and depression.
    • Treatment effectively reverses these immune deficits in schizophrenia but not in depression.
    • Schizophrenia is associated with reversible serum-mediated inhibition of NK activity, which is not observed in depression.